#Germany #Frankfurt #global strategy #Kexing Biopharm #CPHI

Kexing Biopharm Unveils Global Strategy at CPHI Frankfurt 2025

From October 28 to 30, Kexing Biopharm participated in the CPHI Frankfurt 2025, one of the most influential pharmaceutical exhibitions worldwide. The event served as an important platform for the company to present its core product offerings and international commercialization solutions to potential partners in global markets.

During the event, Kexing Biopharm's international business team engaged in productive discussions with industry representatives from various countries. Key topics highlighted included product registration, market access, and localized collaboration strategies. Furthermore, the company showcased its comprehensive expertise across the pharmaceutical value chain, from active pharmaceutical ingredients to finished dosage forms, all supported by internationally compliant quality and regulatory systems.

The CPHI Frankfurt is not merely a venue for product promotion but also plays a vital role in facilitating information exchange and resource integration within the industry. To this end, Kexing’s team actively explored competitor booths, scheduled meetings with clients, and engaged with industry partners on global pharmaceutical trends and political dynamics affecting overseas markets. This proactive approach allowed the company to gather valuable insights, optimizing its overseas expansion strategy while identifying potential customers.

In recent years, Kexing Biopharm has pushed forward with its strategy of “Global Selection + Global Coverage,” identifying and launching high-quality products in oncology, autoimmune diseases, metabolic disorders, and specialty therapies. Through this platform-based internationalization model, Kexing aims to accelerate the commercialization of high-quality Chinese pharmaceuticals worldwide.

Looking toward the future, Kexing Biopharm remains committed to expanding its global presence through open collaboration, efficient business operations, and a patient-centric approach, ensuring that accessible, high-quality healthcare solutions reach patients in more regions.

Kexing Biopharm (Stock Code: 688136.SH) is a multinational biopharmaceutical company engaged in the research, development, manufacturing, and distribution of a diverse range of innovative drugs, including recombinant proteins, antibodies, and cell and gene therapies.

The company seeks to address unmet clinical needs in oncology, autoimmune, and antiviral treatments by establishing cutting-edge technology platforms that facilitate the development of novel targeted therapies and drug delivery systems. Through this approach, Kexing aims to make a significant and meaningful positive impact on the lives of patients.

By pursuing a platform development model driven by innovation and internationalization, Kexing is determined to establish a leading global position in high-quality biopharmaceuticals, thereby improving health outcomes for patients worldwide.